Agilent Technologies and Recent Stock Activity
It's been a while since Agilent Technologies (A) last reported earnings. During this time, their shares have risen by around 1.2%. While that's a positive movement, it’s slightly behind the S&P 500 index's performance. The question now is whether this favorable trend will continue until the next earnings announcement, or if Agilent might experience a downturn.
Let’s take a closer look at Agilent's recent performance and see how analysts and investors are responding to the latest earnings report.
Overview of Agilent's Q3 Results
In the third quarter of fiscal 2024, Agilent Technologies announced earnings of $1.32 per share, beating analyst expectations by 5.6%. However, this figure represents an 8% decline compared to the same time last year.
Agilent's revenues reached $1.58 billion, slightly above the anticipated $1.56 billion, but this marks a 5.6% decrease from the previous year. On a core basis, there was a 4.4% drop. The declines were largely due to ongoing weaknesses across several sectors, including Pharmaceuticals, Food, Chemicals, and advanced materials, as well as in Academic and Government markets.
A sluggish performance in the Chinese market has compounded these concerns. Still, Agilent did see positive developments in the Diagnostics, Clinical, and Environmental sectors during the quarter.
Performance by Segment at Agilent
Agilent divides its revenue into three key segments: Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).
LSAG: This segment brought in $782 million, which accounts for 50% of total revenues. It recorded an 8% decline based on reported figures and a 7% drop on a core basis compared to the previous year. The decline was mainly driven by reduced activity in the instrument sector and mixed performance across various regions, though Environmental and Forensics remained stable.
ACG: Reporting revenues of $411 million, making up 26% of total revenues, ACG exceeded the projected $385 million. It enjoyed a 4% growth year over year in reported numbers and a 5% gain on a core basis, largely due to strong service contract revenue and positive trends in most regions, aside from China.
DGG: This segment saw its revenues drop by 9% on a reported basis and 8% on a core basis, totaling $385 million, which constitutes 24% of total revenues. Though this was better than the expected $332 million, it still faced challenges from declining trends in Genomics and Cell Analysis.
Company Operations and Profit Margins
For fiscal Q3, Agilent's LSAG margin ticked up by 10 basis points to 60.2%. Meanwhile, ACG’s margin greatly improved by 120 basis points to 52.1%. However, DGG’s margin declined by 170 basis points to 51.8% year over year.
Research and Development (R&D) expenditures climbed to $127 million, a 7.6% increase from last year, while Selling, General and Administrative (SG&A) expenses fell to $395 million, a 2.9% drop. As a percentage of revenues, R&D expenses increased by 90 basis points to 8%, with SG&A rising by 70 basis points to 25%.
The overall operating margin for the quarter reached an impressive 21.1%, up from 7.9% in the previous year. Looking at the segments, LSAG's operating margin fell by 260 basis points to 28.4%, ACG's margin improved by 130 basis points to 34%, while DGG’s margin decreased by 440 basis points to 18.3%.
Current Financial Standing
By the end of July 2024, Agilent's cash and cash equivalents had increased to $1.78 billion, up slightly from $1.67 billion in April 2024. Accounts receivable stood at $1.23 billion, down modestly from $1.25 billion at the end of the previous quarter.
Agilent's long-term debt remained steady at $2.137 billion, compared to $2.136 billion in the prior quarter.
Management's Outlook
Looking ahead, Agilent's management projects Q4 revenues to be between $1.641 billion and $1.691 billion, indicating a possible decline of up to 2.8% or a slight increase of up to 0.2% compared to results from a year ago. Non-GAAP earnings per share for the fourth quarter are expected to fall between $1.38 and $1.42.
For fiscal year 2024, revenue is anticipated to fall between $6.45 billion and $6.50 billion, showing a decline of between 5.6% and 4.9% based on reported figures, and between 5% and 4.3% on a core basis compared to fiscal 2023. The non-GAAP earnings projection for fiscal 2024 has also been updated from the previous $5.15-$5.25 to a new forecast of $5.21-$5.25.
Movements in Analysts' Estimates
In recent weeks, a decline in income estimate movements has been observed by investors.
Understanding Agilent's VGM Scores
Currently, Agilent has an average Growth Score of C, indicating steady performance. It also holds a Momentum Score of C. However, it received a D for its Value Score, placing it in the lower 40% for value investment strategies.
Overall, Agilent's aggregate VGM Score is D, which should capture the interest of investors who may not adhere to a specific investment strategy.
Overall Outlook for Agilent
Estimates are generally trending downward, suggesting a potential shift in sentiment concerning Agilent's future performance. Presently, with a Zacks Rank of #3 (Hold), the expectation is for the stock to yield returns that align with the market over the coming months.
Frequently Asked Questions
1. Why has Agilent's stock price increased recently?
Agilent's stock price rose by 1.2% due to better-than-expected earnings results, although challenges in key markets persist.
2. What were Agilent's recent earnings results?
Agilent reported earnings of $1.32 per share, exceeding expectations, but this includes a year-over-year decline.
3. How did Agilent's different segments perform?
The LSAG and DGG segments experienced declines, while ACG showed growth and outperformed expectations.
4. What is Agilent's guidance for the upcoming quarter?
Agilent anticipates revenues between $1.641 billion to $1.691 billion for the next quarter, reflecting cautious optimism amid ongoing challenges.
5. What does the VGM score indicate for Agilent?
Agilent’s overall D VGM score suggests that it struggles against value investment criteria, placing it in the bottom 40% for that strategy.
